Држава: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
THIAMAZOLE
Dechra Limited
QH03BB02
THIAMAZOLE
1.25 mg/tablet
Coated Tablets
POM
Feline
Thiamazole
Miscellaneous
Authorised
2013-09-13
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Felimazole 1.25 mg Coated tablets for cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Coated tablet. Red sugar-coated biconvex tablets 5.5 mm diameter. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long-term treatment of feline hyperthyroidism. 4.3 CONTRAINDICATIONS Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in cats with hypersensitivity to thiamazole or the excipient, polyethylene glycol. Do not use in pregnant or lactating females. Please refer to section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES As thiamazole can cause haemoconcentration, cats should always have access to drinking water. 1 tablet contains: ACTIVE SUBSTANCE: Thiamazole 1.25 mg EXCIPIENTS: Titanium Dioxide (E171) 0.51 mg Dispersed Ponceau 4R Lake (E124) 1.35 mg For a full list of excipients, see section 6.1. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _5_ _/_ _0_ _4_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _6_ _0_ _6_ _2_ _p_ _a_ _g_ Прочитајте комплетан документ